Refractory Chronic Cough Clinical Trial
Official title:
ATP Level in Induced Sputum and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough
This is a prospective case - control study to investigate ATP level in induced sputum and cough sensitivity to ATP in subjects with refractory chronic cough. 60 refractory chronic cough and 30 matched healthy controls were recruited. Medical history records, cough severity assessment, induced sputum for ATP measurement, ATP evoked cough and capsaicin evoked cough were completed. The difference of sputum ATP level between patients and control and the correlation between sputum ATP level and cough sensitivity to ATP were analyzed.
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | May 16, 2023 |
Est. primary completion date | April 16, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Chronic cough as sole symptom lasting =6 months; 2. No potential causes were identified after full investigations or cough persisted after treatment trials directed to potential causes; 3. Cough Visual Analogue Score =30mm. Exclusion Criteria: 1. Current or recent smokers (<6 months abstinence) , those with >20 pack-year smoking history; 2. With a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio <60%; 3. With a history of upper respiratory tract infection or significant change in pulmonary status within 4 weeks. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kefang Lai |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ATP level in sputum | ATP level in induced sputum in subjects with refractory chronic cough and healthy control | 2022/04/01-2023/04/02 | |
Secondary | ATP cough sensitivity | cough sensitivity for ATP in subjects with refractory chronic cough and healthy control | 2022/04/01-2023/04/02 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282591 -
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02476890 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Completed |
NCT03407014 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Recruiting |
NCT05599191 -
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT03662269 -
Indomethacin for Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT05962151 -
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
|
Phase 2 | |
Recruiting |
NCT05110144 -
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Active, not recruiting |
NCT04882943 -
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
|
||
Enrolling by invitation |
NCT05733533 -
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02349425 -
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
|
Phase 2 | |
Recruiting |
NCT05600777 -
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
|
Phase 3 | |
Completed |
NCT05628740 -
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
|
Phase 1 | |
Not yet recruiting |
NCT06213363 -
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
|
Phase 1/Phase 2 | |
Completed |
NCT02412020 -
Treatment of Refractory Chronic Cough With PA101
|
Phase 2 | |
Completed |
NCT04678206 -
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02612623 -
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
|
Phase 2 | |
Completed |
NCT02612610 -
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
|
Phase 2 | |
Completed |
NCT02397460 -
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
|
Phase 2 |